BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Eur J Cancer 2019;107:100-14. [PMID: 30554073 DOI: 10.1016/j.ejca.2018.11.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Ma X, Su J, Zhao S, He Y, Li S, Yang X, Zhai S, Rong S, Zhang X, Xu G, Xie X, Teekaraman Y. CCL3 Promotes Proliferation of Colorectal Cancer Related with TRAF6/NF-κB Molecular Pathway. Contrast Media & Molecular Imaging 2022;2022:1-19. [DOI: 10.1155/2022/2387192] [Reference Citation Analysis]
2 Karin N. Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones? Cancers (Basel) 2021;13:6317. [PMID: 34944943 DOI: 10.3390/cancers13246317] [Reference Citation Analysis]
3 Herting CJ, Farren MR, Tong Y, Liu Z, O'Neil B, Bekaii-Saab T, Noonan A, McQuinn C, Mace TA, Shaib W, Wu C, El-Rayes BF, Shahda S, Lesinski GB. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunol Immunother 2021. [PMID: 34160684 DOI: 10.1007/s00262-021-02986-5] [Reference Citation Analysis]
4 Hemmatazad H, Berger MD. CCR5 is a potential therapeutic target for cancer. Expert Opin Ther Targets 2021;25:311-27. [PMID: 33719836 DOI: 10.1080/14728222.2021.1902505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Karin N. The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative. Front Immunol 2020;11:557586. [PMID: 33193327 DOI: 10.3389/fimmu.2020.557586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]